William D. Waddill insider trades: Protagonist Therapeutics (PTGX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where William reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | PTGX | ↓ Sell | 9,000 | $107.68 | $969K | Direct | Jun 11, 2026 (1d) |
| Feb 6, 2026 | PTGX | ↓ Sell | 20,000 | $83.68 | $1.7M | Direct | Feb 6, 2026 (0d) |
| Dec 19, 2025 | ARWR | ↓ Sell10b5-1 | 8,367 | $67.65 | $566K | Direct | Dec 23, 2025 (4d) |
| Oct 10, 2025 | PTGX | ↓ Sell | 12,000 | $81.62 | $979K | Direct | Oct 14, 2025 (4d) |
| Sep 22, 2025 | PTGX | ↓ Sell | 4,000 | $64.25 | $257K | Direct | Sep 24, 2025 (2d) |
| Aug 27, 2025 | PTGX | ↓ Sell | 4,000 | $59.25 | $237K | Direct | Aug 29, 2025 (2d) |
| Mar 17, 2025 | PTGX | ↓ Sell | 4,000 | $54.25 | $217K | Direct | Mar 19, 2025 (2d) |
| Dec 17, 2024 | ARWR | ↓ Sell | 7,495 | $21.97 | $165K | Direct | Dec 18, 2024 (1d) |
| Sep 10, 2024 | PTGX | ↓ Sell | 8,000 | $45.00 | $360K | Direct | Sep 12, 2024 (2d) |
| Jul 24, 2024 | PTGX | ↓ Sell | 8,000 | $40.00 | $320K | Direct | Jul 26, 2024 (2d) |
| Jun 7, 2024 | PTGX | ↓ Sell | 8,000 | $35.00 | $280K | Direct | Jun 11, 2024 (4d) |
| Mar 1, 2024 | PTGX | ↓ Sell | 12,975 | $31.34 | $407K | Direct | Mar 1, 2024 (0d) |
| Jan 11, 2024 | ARWR | ↓ Sell | 3,934 | $38.07 | $150K | Direct | Jan 16, 2024 (5d) |
| Jan 9, 2023 | ARWR | ↓ Sell10b5-1 | 3,200 | $30.00 | $96K | Direct | Jan 11, 2023 (2d) |
| Jan 3, 2022 | ARWR | ↓ Sell10b5-1 | 4,500 | $64.72 | $291K | Direct | Jan 4, 2022 (1d) |
| Jan 4, 2021 | ARWR | ↓ Sell | 3,750 | $76.08 | $285K | Direct | Jan 5, 2021 (1d) |
| Dec 10, 2020 | ARWR | ↓ Sell | 3,000 | $71.26 | $214K | Direct | Dec 11, 2020 (1d) |
| May 11, 2020 | ARWR | ↓ Sell | 26,000 | $36.54 | $950K | Direct | May 13, 2020 (2d) |
| Jan 11, 2019 | ARWR | ↓ Sell | 8,500 | $14.77 | $126K | Direct | Jan 11, 2019 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PTGX insiders
Open-market trades in the last 12 months
About William D. Waddill's insider trades
William D. Waddill is a director at Protagonist Therapeutics (PTGX). Since Jan 11, 2019, William has reported no open-market purchases and 19 sales worth $8.5M on SEC Form 4. In the last 12 months: 3 sales ($3.2M).
3 sales (11% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (32 filings), option exercises (10 filings), other transactions (1 filing), conversions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PTGX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.